MORC2
ATPase MORC2
Also known as: AC004542.C22.1, KIAA0852, MORC2_HUMAN, ZCW3, ZCWCC1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y6X9
- Gene
- MORC2
- Ensembl
- ENSG00000133422
- Chromosome
- 22
- Canonical length
- 1032 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the Microrchidia (MORC) protein superfamily. The encoded protein is known to regulate the condensation of heterochromatin in response to DNA damage and play a role in repressing transcription. The protein has been found to regulate the activity of ATP citrate lyase via specific interaction with this enzyme in the cytosol of lipogenic breast cancer cells. The protein also plays a role in lipogenesis and adipocyte differentiation. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2016]
Canonical amino-acid sequenceUniProt
1032 residues, UniProt reviewed canonical sequence.
>Q9Y6X9|MORC2
1 MAFTNYSSLN RAQLTFEYLH TNSTTHEFLF GALAELVDNA RDADATRIDI YAERREDLRG
61 GFMLCFLDDG AGMDPSDAAS VIQFGKSAKR TPESTQIGQY GNGLKSGSMR IGKDFILFTK
121 KEDTMTCLFL SRTFHEEEGI DEVIVPLPTW NARTREPVTD NVEKFAIETE LIYKYSPFRT
181 EEEVMTQFMK IPGDSGTLVI IFNLKLMDNG EPELDIISNP RDIQMAETSP EGTKPERRSF
241 RAYAAVLYID PRMRIFIHGH KVQTKRLSCC LYKPRMYKYT SSRFKTRAEQ EVKKAEHVAR
301 IAEEKAREAE SKARTLEVRL GGDLTRDSRV MLRQVQNRAI TLRREADVKK RIKEAKQRAL
361 KEPKELNFVF GVNIEHRDLD GMFIYNCSRL IKMYEKVGPQ LEGGMACGGV VGVVDVPYLV
421 LEPTHNKQDF ADAKEYRHLL RAMGEHLAQY WKDIAIAQRG IIKFWDEFGY LSANWNQPPS
481 SELRYKRRRA MEIPTTIQCD LCLKWRTLPF QLSSVEKDYP DTWVCSMNPD PEQDRCEASE
541 QKQKVPLGTF RKDMKTQEEK QKQLTEKIRQ QQEKLEALQK TTPIRSQADL KKLPLEVTTR
601 PSTEEPVRRP QRPRSPPLPA VIRNAPSRPP SLPTPRPASQ PRKAPVISST PKLPALAARE
661 EASTSRLLQP PEAPRKPANT LVKTASRPAP LVQQLSPSLL PNSKSPREVP SPKVIKTPVV
721 KKTESPIKLS PATPSRKRSV AVSDEEEVEE EAERRKERCK RGRFVVKEEK KDSNELSDSA
781 GEEDSADLKR AQKDKGLHVE VRVNREWYTG RVTAVEVGKH VVRWKVKFDY VPTDTTPRDR
841 WVEKGSEDVR LMKPPSPEHQ SLDTQQEGGE EEVGPVAQQA IAVAEPSTSE CLRIEPDTTA
901 LSTNHETIDL LVQILRNCLR YFLPPSFPIS KKQLSAMNSD ELISFPLKEY FKQYEVGLQN
961 LCNSYQSRAD SRAKASEESL RTSERKLRET EEKLQKLRTN IVALLQKVQE DIDINTDDEL
1021 DAYIEDLITK GDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MORC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 23 nTPM
Expression across tissuesHPA
Tissue
- testis: 23 nTPM
- skeletal muscle: 16 nTPM
- blood vessel: 12 nTPM
- skin: 9.6 nTPM
- tongue: 9.5 nTPM
- liver: 9.3 nTPM
Single-cell type
- myonuclei: 52 nCPM
- early spermatids: 44 nCPM
- early primary spermatocytes: 42 nCPM
- medullary thymic epithelial cells: 36 nCPM
- bergmann glia: 32 nCPM
- late primary spermatocytes: 32 nCPM
Immune cell
- T-reg: 17 nTPM
- naive CD4 T-cell: 15 nTPM
- memory CD4 T-cell: 15 nTPM
- gdT-cell: 12 nTPM
- naive CD8 T-cell: 11 nTPM
- MAIT T-cell: 10 nTPM
Brain region
- cerebellum: 16 nTPM
- midbrain: 13 nTPM
- white matter: 13 nTPM
- thalamus: 13 nTPM
- pons: 13 nTPM
- basal ganglia: 13 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MORC2.
Disease | AllUniProt
Conditions MORC2 is implicated in, by any mechanism.
- Charcot-Marie-Tooth disease, axonal, type 2Z (CMT2Z) MIM:616688
- Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy (DIGFAN) MIM:619090
Disease | GeneticClinVar
35 pathogenic / likely-pathogenic of 1,064 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Charcot-Marie-Tooth disease axonal type 2Z
- Developmental delay, impaired growth, dysmorphic facies, and axonal neuropathy
- Charcot-Marie-Tooth disease
- Inborn genetic diseases
- MORC2-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.21
- gnomAD pLI
- 1
- gnomAD missense Z
- 3.23
- DepMap mean gene effect
- -0.16
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- chromatin remodeling
- constitutive heterochromatin formation
- DNA damage response
- fatty acid metabolic process
- transposable element silencing by heterochromatin formation
Molecular functions
- ATP binding
- ATP hydrolysis activity
- ATP-dependent chromatin remodeler activity
- chromatin binding
- identical protein binding
- magnesium ion binding
- protein homodimerization activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Zinc finger, CW-type
- Histidine kinase/HSP90-like ATPase superfamily
- Morc, S5 domain 2-like
- CW-type Zinc Finger
- Histidine kinase-, DNA gyrase B-, and HSP90-like ATPase
- Morc6 ribosomal protein S5 domain 2-like
- ATPase MORC2, chromo domain-like
- ATPase MORC2, chromo domain-like
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MORC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MORC2 as an antibody target. Whether an autoantibody or antibody against MORC2 could matter depends on whether native MORC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MORC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MORC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...